{"id":66050,"date":"2026-05-23T22:08:48","date_gmt":"2026-05-23T14:08:48","guid":{"rendered":"https:\/\/flcube.com\/?p=66050"},"modified":"2026-05-23T22:08:49","modified_gmt":"2026-05-23T14:08:49","slug":"lupeng-pharma-enrolls-first-patient-in-global-phase-3-rocket-cll-trial-of-fourth-gen-btk-inhibitor-rocbrutinib-vs-pirtobrutinib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66050","title":{"rendered":"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lupeng Pharmaceutical Ltd.<\/strong> announced the enrollment of the first patient in its global <strong>Phase 3 ROCKET-CLL trial<\/strong> (NCT07342478), evaluating <strong>rocbrutinib (LP-168)<\/strong>, a novel <strong>fourth-generation Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/strong>, against <strong>pirtobrutinib<\/strong> in patients with <strong>relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL)<\/strong> who have received prior therapy with a covalent BTK inhibitor (cBTKi).<\/p>\n\n\n\n<h2 id=\"h-trial-design-amp-enrollment\" class=\"wp-block-heading\">Trial Design &amp; Enrollment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Name<\/strong><\/td><td>ROCKET-CLL (NCT07342478)<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase 3<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Randomized, open-label, multicenter<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adult patients with R\/R CLL\/SLL post cBTKi<\/td><\/tr><tr><td><strong>Planned Enrollment<\/strong><\/td><td>~306 patients globally<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-free survival (PFS)<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Overall response rate (ORR), duration of response (DOR), safety profile<\/td><\/tr><tr><td><strong>First Patient Enrolled<\/strong><\/td><td>21 May 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Rocbrutinib (LP-168) \u2013 fourth-generation oral BTK inhibitor<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Developed on Lupeng&#8217;s proprietary <strong>BeyondX platform<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Combines <strong>covalent (irreversible)<\/strong> and <strong>non-covalent (reversible)<\/strong> binding mechanisms<\/li>\n\n\n\n<li><strong>Target Coverage:<\/strong> Inhibits both <strong>wild-type<\/strong> and <strong>C481-mutant BTK<\/strong><\/li>\n\n\n\n<li><strong>Resistance Profile:<\/strong> Engineered to overcome multiple resistance mutations including <strong>C481X, T474X, and L528W<\/strong><\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Best-in-class potential in post-cBTKi setting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-context-amp-competitive-landscape\" class=\"wp-block-heading\">Clinical Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Rocbrutinib (LP-168)<\/th><th>Pirtobrutinib<\/th><th>Other Next-Gen BTKis<\/th><\/tr><\/thead><tbody><tr><td><strong>Generation<\/strong><\/td><td>Fourth<\/td><td>Third<\/td><td>Second\/Third<\/td><\/tr><tr><td><strong>Binding Mechanism<\/strong><\/td><td>Dual (covalent + non-covalent)<\/td><td>Non-covalent only<\/td><td>Primarily covalent<\/td><\/tr><tr><td><strong>C481 Mutation Coverage<\/strong><\/td><td>Yes<\/td><td>Yes<\/td><td>Limited\/None<\/td><\/tr><tr><td><strong>Additional Mutations Targeted<\/strong><\/td><td>C481X, T474X, L528W<\/td><td>Primarily C481<\/td><td>Variable<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Head-to-head vs. pirtobrutinib<\/td><td>Approved based on single-arm trials<\/td><td>Various<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>ROCKET-CLL trial<\/strong> represents one of the first direct head-to-head comparisons between next-generation BTK inhibitors in the post-covalent BTK inhibitor setting, where treatment options remain limited despite the high unmet medical need.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-development-outlook\" class=\"wp-block-heading\">Market Impact &amp; Development Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global CLL Market:<\/strong> Projected to reach <strong>$8.2 billion by 2030<\/strong>, with next-generation BTK inhibitors representing the fastest-growing segment<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Approximately <strong>30-40% of CLL patients<\/strong> develop resistance to covalent BTK inhibitors within 2-3 years of treatment initiation<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Rocbrutinib&#8217;s dual-binding mechanism may provide superior efficacy against diverse resistance mutations compared to single-mechanism inhibitors<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Full enrollment expected by <strong>Q2 2028<\/strong>, with top-line results anticipated in <strong>H2 2028<\/strong><\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Lupeng is preparing for potential global regulatory submissions following successful trial completion<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, trial outcomes, and market potential for rocbrutinib. Actual results may differ materially due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,3432,33],"class_list":["post-66050","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-lupeng-pharmaceutical","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton&#039;s tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66050\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib\" \/>\n<meta property=\"og:description\" content=\"Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton&#039;s tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66050\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-23T14:08:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-23T14:08:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66050#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66050\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib\",\"datePublished\":\"2026-05-23T14:08:48+00:00\",\"dateModified\":\"2026-05-23T14:08:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66050\"},\"wordCount\":404,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Lupeng Pharmaceutical\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66050#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66050\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66050\",\"name\":\"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-23T14:08:48+00:00\",\"dateModified\":\"2026-05-23T14:08:49+00:00\",\"description\":\"Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton's tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\\\/small lymphocytic lymphoma (R\\\/R CLL\\\/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66050#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66050\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66050#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib - Insight, China&#039;s Pharmaceutical Industry","description":"Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton's tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66050","og_locale":"en_US","og_type":"article","og_title":"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib","og_description":"Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton's tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).","og_url":"https:\/\/flcube.com\/?p=66050","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-23T14:08:48+00:00","article_modified_time":"2026-05-23T14:08:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66050#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66050"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib","datePublished":"2026-05-23T14:08:48+00:00","dateModified":"2026-05-23T14:08:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66050"},"wordCount":404,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Lupeng Pharmaceutical","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66050#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66050","url":"https:\/\/flcube.com\/?p=66050","name":"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-23T14:08:48+00:00","dateModified":"2026-05-23T14:08:49+00:00","description":"Lupeng Pharmaceutical Ltd. announced the enrollment of the first patient in its global Phase 3 ROCKET-CLL trial (NCT07342478), evaluating rocbrutinib (LP-168), a novel fourth-generation Bruton's tyrosine kinase (BTK) inhibitor, against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) who have received prior therapy with a covalent BTK inhibitor (cBTKi).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66050#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66050"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66050#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66050"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66050\/revisions"}],"predecessor-version":[{"id":66052,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66050\/revisions\/66052"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}